Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab Q2W vs Q4W dosing in moderate-to-severe plaque psoriasis
2015-000190-12Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ixekizumab in plaque psoriasis (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: sPGA (0,1) response and PASI 75 response. Started May 2015; status: completed.
02
Drugs
ixekizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2015-000190-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000190-12.